Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 1,270 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 1,270 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $23.25, for a total transaction of $29,527.50. Following the transaction, the director now directly owns 130,373 shares in the company, valued at $3,031,172.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Enliven Therapeutics Stock Down 0.8 %

ELVN traded down $0.18 during trading on Monday, hitting $23.53. 140,925 shares of the company traded hands, compared to its average volume of 264,869. The firm has a market cap of $1.11 billion, a P/E ratio of -11.95 and a beta of 1.10. Enliven Therapeutics, Inc. has a one year low of $9.80 and a one year high of $27.67. The stock’s fifty day moving average is $22.90 and its 200 day moving average is $20.16.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. On average, equities research analysts forecast that Enliven Therapeutics, Inc. will post -2.26 EPS for the current fiscal year.

Analyst Ratings Changes

ELVN has been the topic of several research reports. Robert W. Baird initiated coverage on shares of Enliven Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price objective on the stock. Baird R W upgraded shares of Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ELVN. AJOVista LLC purchased a new stake in Enliven Therapeutics in the fourth quarter valued at approximately $28,000. Quest Partners LLC raised its stake in Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after purchasing an additional 742 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Enliven Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock valued at $140,000 after purchasing an additional 3,189 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in Enliven Therapeutics in the first quarter valued at approximately $167,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Enliven Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after purchasing an additional 1,029 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.